199 related articles for article (PubMed ID: 35725817)
1. Inhibition of BAD-Ser99 phosphorylation synergizes with PARP inhibition to ablate PTEN-deficient endometrial carcinoma.
Zhang X; Huang P; Wang L; Chen S; Basappa B; Zhu T; Lobie PE; Pandey V
Cell Death Dis; 2022 Jun; 13(6):558. PubMed ID: 35725817
[TBL] [Abstract][Full Text] [Related]
2. PTEN deficiency sensitizes endometrioid endometrial cancer to compound PARP-PI3K inhibition but not PARP inhibition as monotherapy.
Bian X; Gao J; Luo F; Rui C; Zheng T; Wang D; Wang Y; Roberts TM; Liu P; Zhao JJ; Cheng H
Oncogene; 2018 Jan; 37(3):341-351. PubMed ID: 28945226
[TBL] [Abstract][Full Text] [Related]
3. Inhibition of PI3K-AKT-mTOR pathway sensitizes endometrial cancer cell lines to PARP inhibitors.
Philip CA; Laskov I; Beauchamp MC; Marques M; Amin O; Bitharas J; Kessous R; Kogan L; Baloch T; Gotlieb WH; Yasmeen A
BMC Cancer; 2017 Sep; 17(1):638. PubMed ID: 28886696
[TBL] [Abstract][Full Text] [Related]
4. Combined inhibition of BADSer99 phosphorylation and PARP ablates models of recurrent ovarian carcinoma.
Zhang X; Wang L; Chen S; Huang P; Ma L; Ding H; Basappa B; Zhu T; Lobie PE; Pandey V
Commun Med (Lond); 2022; 2():82. PubMed ID: 35791346
[TBL] [Abstract][Full Text] [Related]
5. PTEN deficiency in endometrioid endometrial adenocarcinomas predicts sensitivity to PARP inhibitors.
Dedes KJ; Wetterskog D; Mendes-Pereira AM; Natrajan R; Lambros MB; Geyer FC; Vatcheva R; Savage K; Mackay A; Lord CJ; Ashworth A; Reis-Filho JS
Sci Transl Med; 2010 Oct; 2(53):53ra75. PubMed ID: 20944090
[TBL] [Abstract][Full Text] [Related]
6. Acquired resistance of phosphatase and tensin homolog-deficient cells to poly(ADP-ribose) polymerase inhibitor and Ara-C mediated by 53BP1 loss and SAMHD1 overexpression.
Wang YT; Yuan B; Chen HD; Xu L; Tian YN; Zhang A; He JX; Miao ZH
Cancer Sci; 2018 Mar; 109(3):821-831. PubMed ID: 29274141
[TBL] [Abstract][Full Text] [Related]
7. Anti-tumor activity of olaparib, a poly (ADP-ribose) polymerase (PARP) inhibitor, in cultured endometrial carcinoma cells.
Miyasaka A; Oda K; Ikeda Y; Wada-Hiraike O; Kashiyama T; Enomoto A; Hosoya N; Koso T; Fukuda T; Inaba K; Sone K; Uehara Y; Kurikawa R; Nagasaka K; Matsumoto Y; Arimoto T; Nakagawa S; Kuramoto H; Miyagawa K; Yano T; Kawana K; Osuga Y; Fujii T
BMC Cancer; 2014 Mar; 14():179. PubMed ID: 24625059
[TBL] [Abstract][Full Text] [Related]
8. Histone deacetylase inhibitor, suberoylanilide hydroxamic acid (SAHA), enhances anti-tumor effects of the poly (ADP-ribose) polymerase (PARP) inhibitor olaparib in triple-negative breast cancer cells.
Min A; Im SA; Kim DK; Song SH; Kim HJ; Lee KH; Kim TY; Han SW; Oh DY; Kim TY; O'Connor MJ; Bang YJ
Breast Cancer Res; 2015 Mar; 17():33. PubMed ID: 25888415
[TBL] [Abstract][Full Text] [Related]
9. A novel dopamine receptor D2 antagonist (ONC206) potentiates the effects of olaparib in endometrial cancer.
Paraghamian SE; Qiu J; Hawkins GM; Zhao Z; Sun W; Fan Y; Zhang X; Suo H; Hao T; Prabhu VV; Allen JE; Zhou C; Bae-Jump V
Cancer Biol Ther; 2023 Dec; 24(1):2202104. PubMed ID: 37069726
[TBL] [Abstract][Full Text] [Related]
10. An effective AKT inhibitor-PARP inhibitor combination therapy for recurrent ovarian cancer.
Xu J; Gao Y; Luan X; Li K; Wang J; Dai Y; Kang M; Lu C; Zhang M; Lu CX; Kang Y; Xu C
Cancer Chemother Pharmacol; 2022 May; 89(5):683-695. PubMed ID: 35419627
[TBL] [Abstract][Full Text] [Related]
11. Low levels of circulating estrogen sensitize PTEN-null endometrial tumors to PARP inhibition in vivo.
Janzen DM; Paik DY; Rosales MA; Yep B; Cheng D; Witte ON; Kayadibi H; Ryan CM; Jung ME; Faull K; Memarzadeh S
Mol Cancer Ther; 2013 Dec; 12(12):2917-28. PubMed ID: 24222661
[TBL] [Abstract][Full Text] [Related]
12. TRAF4 knockdown triggers synergistic lethality with simultaneous PARP1 inhibition in endometrial cancer.
Tang L; Wang M; Jiang L; Zeng C
Hum Cell; 2020 Jul; 33(3):801-809. PubMed ID: 32388810
[TBL] [Abstract][Full Text] [Related]
13. Metabolism-focused CRISPR screen unveils mitochondrial pyruvate carrier 1 as a critical driver for PARP inhibitor resistance in lung cancer.
Furusawa T; Cavero R; Liu Y; Li H; Xu X; Andresson T; Reinhold W; White O; Boufraqech M; Meyer TJ; Hartmann O; Diefenbacher ME; Pommier Y; Weyemi U
Mol Carcinog; 2024 Jun; 63(6):1024-1037. PubMed ID: 38411275
[TBL] [Abstract][Full Text] [Related]
14. EGFR- and AKT-mediated reduction in PTEN expression contributes to tyrphostin resistance and is reversed by mTOR inhibition in endometrial cancer cells.
Li T; Yang Y; Li X; Xu C; Meng L
Mol Cell Biochem; 2012 Feb; 361(1-2):19-29. PubMed ID: 21952748
[TBL] [Abstract][Full Text] [Related]
15. Combined poly-ADP ribose polymerase and ataxia-telangiectasia mutated/Rad3-related inhibition targets ataxia-telangiectasia mutated-deficient lung cancer cells.
Jette NR; Radhamani S; Arthur G; Ye R; Goutam S; Bolyos A; Petersen LF; Bose P; Bebb DG; Lees-Miller SP
Br J Cancer; 2019 Oct; 121(7):600-610. PubMed ID: 31481733
[TBL] [Abstract][Full Text] [Related]
16. Use of antioxidant nanoliposomes for co-delivery of PTEN plasmids and plumbagin to induce apoptosis in hepatic cancer cells.
Bhagat S; Singh S
Biomed Mater; 2024 Feb; 19(2):. PubMed ID: 38215478
[TBL] [Abstract][Full Text] [Related]
17. Research Progress of PARP Inhibitor Monotherapy and Combination Therapy for Endometrial Cancer.
Shen K; Yang L; Li FY; Zhang F; Ding LL; Yang J; Lu J; Wang NN; Wang Y
Curr Drug Targets; 2022; 23(2):145-155. PubMed ID: 34139979
[TBL] [Abstract][Full Text] [Related]
18. Activation of the PI3K/mTOR Pathway following PARP Inhibition in Small Cell Lung Cancer.
Cardnell RJ; Feng Y; Mukherjee S; Diao L; Tong P; Stewart CA; Masrorpour F; Fan Y; Nilsson M; Shen Y; Heymach JV; Wang J; Byers LA
PLoS One; 2016; 11(4):e0152584. PubMed ID: 27055253
[TBL] [Abstract][Full Text] [Related]
19. Genotype-dependent efficacy of a dual PI3K/mTOR inhibitor, NVP-BEZ235, and an mTOR inhibitor, RAD001, in endometrial carcinomas.
Shoji K; Oda K; Kashiyama T; Ikeda Y; Nakagawa S; Sone K; Miyamoto Y; Hiraike H; Tanikawa M; Miyasaka A; Koso T; Matsumoto Y; Wada-Hiraike O; Kawana K; Kuramoto H; McCormick F; Aburatani H; Yano T; Kozuma S; Taketani Y
PLoS One; 2012; 7(5):e37431. PubMed ID: 22662154
[TBL] [Abstract][Full Text] [Related]
20. Rad51 Degradation: Role in Oncolytic Virus-Poly(ADP-Ribose) Polymerase Inhibitor Combination Therapy in Glioblastoma.
Ning J; Wakimoto H; Peters C; Martuza RL; Rabkin SD
J Natl Cancer Inst; 2017 Mar; 109(3):1-13. PubMed ID: 28376211
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
